Recent advances in molecular gynaecological pathology.
This review gives an overview of recent advances in our understanding of the molecular basis of gynaecological malignancy, including cervical, vulval, endometrial and ovarian tumours. These advances are beginning to influence clinical practice, perhaps most notably with the introduction of human papillomavirus vaccination for the prevention of anogenital neoplasia, but are likely to have broader clinical implications as further details emerge.
Herrington
C Simon
CS
Bute Medical School, University of St Andrews, St Andrews, UK. csh2@st-andrews.ac.uk
D052685:Alphapapillomavirus / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity; D019496:Cancer Vaccines; D005260:Female; D005833:Genital Neoplasms, Female / Q000235:genetics* / Q000473:pathology* / Q000821:virology; D006801:Humans; D030361:Papillomavirus Infections / Q000235:genetics / Q000517:prevention & control / Q000821:virology; D053918:Papillomavirus Vaccines; D010336:Pathology / Q000639:trends*; D002583:Uterine Cervical Neoplasms / Q000235:genetics / Q000473:pathology / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000235:genetics / Q000473:pathology / Q000821:virology
D019496:Cancer Vaccines; D053918:Papillomavirus Vaccines